AKT1 and prostate cancer: HSPB6 was reported to suppress the MAPK family, including JNK and the PI3K/Akt pathway (Matsushima-Nishiwaki et al., 2011, 2013), and the downregulated ACACA curbed prostate cancer growth (Zhang et al., 2021).